AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...

European stocks plunged sharply, and several markets tumbled to fresh multi-month lows on Friday as US President Donald Trump ...

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

The NIH is scrambling to slash $2.6 billion in contracts — about 35% of them — by April 8, per the instruction of the U.S.

On The Readout LOUD podcast, STAT reporters talk about new FDA commissioner Marty Makary's first week amid a swirl of layoffs ...

Enhertu gains EU approval for treating advanced breast cancer with low HER2 levels, marking a milestone for Daiichi Sankyo & ...

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

Ferric carboxymaltose, an IV iron replacement therapy, did not reduce the time to first HF hospitalization or CV death for patients with HF and iron deficiency, according to results of a late-breaking ...

Imfinzi in combination with chemotherapy has been approved in the European Union, EU, for the treatment of adults with ...

As CEOs continue to digest the fallout of the murder of UnitedHealthcare CEO Brian Johnson, a billionaire backer of major companies believes a pay rise is needed to attract them to the job. Lord ...

Learn more about whether Ionis Pharmaceuticals, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.